Correspondence 0001193125-24-154232 from Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc.
Date: June 4, 2024 · CIK: 0002012593 · Accession: 0001193125-24-154232
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279486
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Tamika Sheppard, Joe McCann, Daniel Gordon and Jenn Do Re: Rapport Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-279486
Dear Ladies and Gentlemen,
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Rapport Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 6, 2024 at 4:00 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Justin S. Platt at (212) 459-7340.
If you have any questions regarding this request, please contact Justin S. Platt of Goodwin Procter LLP at (212) 459 7340.
Sincerely,
RAPPORT THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR June 4, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Tamika Sheppard, Joe McCann, Daniel Gordon and Jenn Do Re: Rapport Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-279486 Dear Ladies and Gentlemen, Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Rapport Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 6, 2024 at 4:00 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Justin S. Platt at (212) 459-7340. If you have any questions regarding this request, please contact Justin S. Platt of Goodwin Procter LLP at (212) 459 7340. Sincerely, RAPPORT THERAPEUTICS, INC. /s/ Troy Ignelzi Troy Ignelzi Chief Financial Officer cc: Abraham N. Ceesay, Rapport Therapeutics, Inc. Kingsley L. Taft, Goodwin Procter LLP Stephanie A. Richards, Goodwin Procter LLP Justin S. Platt, Goodwin Procter LLP